Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey - 2US FDA declines to approve Corcept's drug for rare hormonal disorder
- 3Nepal’s youngest premier sworn in after releasing new rap song about unity
- 4A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- 5Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- Taylor Swift just released the 'Elizabeth Taylor' music video — but she's not the star of it
- Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
- Why the Houthis waited until now to strike
- Happy with Running Shoes for 2024
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Pick Your Favored kind of books
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- The most effective method to Pick The Right Speakers
